2023 The Final Countdown

  1. 4,409 Posts.
    lightbulb Created with Sketch. 5736
    Dr Eric Rose - Chief Medical Officer Mesoblast June 30th webcast 2022

    " Let me go back though to GvHD. To say we are not excited about this would be the understatement I think of the century. There are drugs approved recently for chronic GvHD with now two companies that have achieved more than a billion dollar valuation with that indication. We think we are going to be right in that range. This is a whole new class of theraputics, there is no off the shelf stem cell, or any cell product as far as I know aside from drug transfusions that is approved by FDA for theraputic use. The company stands at the precipice of a breakthrough in this regard for a class of therapeutics that I think will have wide use in multiple diseases, and we think it will be valued for that as well."

    Dr Silviu Itescu - CEO Mesoblast Sep 30th webcast 2022

    " In particular the only drug that has been approved to date for SrGvHD is Ruxolitinib. It was approved on the basis of a single open arm study, when it subsequently did a randomised control trial it was required to do in a post approval commitment, there was no survival benefit in Sr GvHD. Independent investigators more recently published a significant survival benefit with remestemcel in children with the highest risk of mortality where survival in the controls was in the order of 10%, and survival in remestemcel treated children was in the order of 64%. "


    CHF FDA RMAT meeting
    - estimated end of Feb 2023

    CLPB pivotal USA trial commence
    - expected April - June 2023

    Remestemcel PDUFA date
    - estimated by June 2023

    CHF partnership announcement - estimated after the RMAT meeting

    ARDS trial announced - estimated H2 2023

    Ryoncil phase 4 in adults - estimated H2 2023

    2022 was the year of the popcorn, now it's main event time !

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.84
Change
0.185(11.2%)
Mkt cap ! $2.338B
Open High Low Value Volume
$1.66 $1.84 $1.65 $13.70M 7.780M

Buyers (Bids)

No. Vol. Price($)
2 53212 $1.84
 

Sellers (Offers)

Price($) Vol. No.
$1.84 39565 9
View Market Depth
Last trade - 16.15pm 01/07/2025 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.